Prostate cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ADT, Abiraterone, Apalutamide Variant #01 | — | R 574 841 | — | — | — | — | — | — |
Enzalutamide and Leuprolide Variant #01 | — | R 48 118 | 84d | — | — | — | — | 1 |
Enzalutamide monotherapy Variant #01 | — | R 14 528 | 28d | 4.2 mo | 17.5 mo | 5 | R 72 642 PFS proxy | 13 |
Leuprolide monotherapy Variant #01 | — | R 2 266 | 90d | — | — | — | — | 2 |
ADT and Apalutamide Variant #01 | — | R 1 206 | — | — | 73.9 mo | — | — | 2 |
ADT Variant #01 Partial | — | — | — | — | 52.0 mo | — | — | 14 |
6 of 6 regimens shown